

Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. *Blood Adv.* 2020;4(21):5414-5424.

There are errors in the cytokine release syndrome (“CRS”) section of Table 2 on page 5417. In the “ELIANA” column, the median number of days to onset should read “3,” the range of days to onset should read “1-22,” the median number of days of duration should read “8,” and the range of days of duration should read “1-36.” In the “JULIET” column, the range of days to onset should read “1-51,” the median number of days of duration should read “7,” and the range of days of duration should read “2-30.”

In the “MRD⁻” row of the “Pivotal trial, % (95% CI)” column of Table 3 on page 5419, “100.0 (n = 64/64)” should read “98.5 (n = 64/65).”

The corrected Tables 2 and 3 are shown below. The errors have been corrected in the published article.

DOI 10.1182/bloodadvances.2021004265

© 2021 by The American Society of Hematology

Table 2. Comparison of safety outcomes of CIBMTR with those of ELIANA and JULIET trials

End point	ALL		NHL	
	CIBMTR (n = 255)	ELIANA (n = 79)	CIBMTR (n = 155)	JULIET (n = 115)
CRS				
Any, n (%)	140 (54.9)	61 (77.2)	70 (45.2)	66 (57.4)
Grade ≥3, n (%)	41 (16.1)	38 (48.1)	7 (4.5)	26 (22.6)
Time to onset, d				
Median	6	3	4	3
Range	1-27	1-22	1-14	1-51
Duration, d				
Median	7	8	5	7
Range	1-76	1-36	1-33	2-30
Neurotoxicity				
Any, n (%)	69 (27.1)	31 (39.2)	28 (18.1)	23 (20.0)
Grade ≥3, n (%)	23 (9.0)	10 (12.7)	8 (5.1)	13 (11.3)
Time to onset, d				
Median	7	8	8	6
Range	1-80	2-489	2-33	1-323
Duration, d				
Median	7	7	6.5	13
Range	1-94		1-50	

Table 3. Comparison of efficacy outcomes of CIBMTR with those of ELIANA and JULIET trials

End point	CIBMTR, % (95% CI)	Pivotal trial, % (95% CI)
CIBMTR vs ELIANA (n = 249) (n = 79)		
BOR of CR	85.5 (80.6-89.7)	82.3 (72.1-90.0)
MRD ⁻	99.1 (n = 115/116) (95.3-100)	98.5 (n = 64/65) (94.4-100)
DOR		
At 6 mo	78.1 (70.5-84.0)	80.8 (68.0-88.9)
At 12 mo	60.9 (49.4-70.5)	67.4 (53.2-78.1)
EFS		
At 6 mo	68.6 (62.0-74.4)	71.7 (59.8-80.6)
At 12 mo	52.4 (43.4-60.7)	57.2 (44.5-68.0)
OS		
At 6 mo	88.5 (83.6-92.0)	88.6 (79.3-93.9)
At 12 mo	77.2 (69.8-83.1)	77.1 (66.1-84.9)
CIBMTR vs JULIET (n = 152) (n = 115)		
ORR (CR + PR)	61.8 (53.6-69.6)	52.2 (42.7-61.6)
BOR of CR	39.5 (31.6-47.7)	38.3 (29.4-47.8)
DOR		
At 6 mo	55.3 (42.2-66.6)	66.6 (52.8-77.3)
At 12 mo	48.4* (33.9-61.5)	62.7 (48.7-73.9)
PFS		
At 6 mo	38.7 (30.5-46.9)	39.0 (29.7-48.2)
At 12 mo	26.4* (17.2-36.6)	34.7 (25.7-43.9)
OS		
At 6 mo	70.7 (62.2-77.6)	61.2 (51.6-69.5)
At 12 mo	56.3 (44.2-66.8)	48.2 (38.6-57.1)

*Less than 10 patients at risk at this time point.